Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

    Funding for Alzheimer's drug development from pre-clinical to Phase I clinical trials to prevent, slow, or treat AD symptoms, excluding basic research and non-pharmacological interventions.

    Browse similar grants
    Neuroscience Research Grants 2026
    OverviewSimilar Grants
    OverviewSimilar Grants

    Alzheimers Drug-Development Program (U01 Clinical Trial Optional)

    This grant supports academic and biotech researchers in developing new drugs to prevent, slow, or treat Alzheimer’s disease through preclinical and early-stage clinical research.

    HHS-NIH11Forecasted Jun 18, 2027Forecasted

    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

    This grant supports combined Phase 1/2a clinical trials testing new drugs (excluding amyloid/tau targets) for Alzheimer's, using a milestone-driven approach.

    HHS-NIH11Due Nov 19, 2026· 3d

    Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

    Use mouse models to test existing and investigational drugs for Alzheimer's; focus on drug repositioning and combo therapy development.

    HHS-NIH11Due Feb 8, 2027$5,000,000

    Drug Development RFP

    Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.

    Alzheimers Drug DiscoveryDue Dec 7, 2026· 21d$5,000,000

    Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

    NIH supports genome editing and other biologic therapies for Alzheimer's disease-related dementias, from lead optimization and drug development through safety studies and early clinical evaluation.

    HHS-NIH11Due Feb 9, 2027$12,500,000